arsenic trioxide has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, JH; Chung, HJ; Hwang, DW; Kim, ES; Kim, JS; Kim, S; Lee, SK; Lee, YY; Park, BB; Uhm, J; Won, YW; Yi, JH; Yoon, JS | 1 |
| Ahuja, HG; Bailey, HH; Chang, JE; Kahl, BS; Kim, K; Kolesar, JM; Rodriguez, GA; Sanchez, FA; Voorhees, PM; Werndli, J | 1 |
| Dong, ZR; Du, XY; Li, Y; Liu, XJ; Luo, JM; Wen, SP; Yang, JC; Yang, L; Yao, L | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Fujisawa, S; Naito, K; Nakamura, S; Ohnishi, K; Ohno, R; Shigeno, K; Takeshita, A; Takeshita, K; Zhang, W | 1 |
1 trial(s) available for arsenic trioxide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Phase II study of arsenic trioxide and ascorbic acid for relapsed or refractory lymphoid malignancies: a Wisconsin Oncology Network study.
Topics: Adult; Aged; Aged, 80 and over; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Female; Glutathione; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Male; Middle Aged; Oxides; Safety | 2009 |
4 other study(ies) available for arsenic trioxide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin's lymphoma: an in vitro and in vivo study.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Arsenites; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Jurkat Cells; Lymphoma, Non-Hodgkin; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Oxides; Pilot Projects; Signal Transduction; Sodium Compounds; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
[As2O3 induces demethylation and up-regulates transcription of SHP-1 gene in human lymphoma cell line T2 cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Line, Tumor; Cell Proliferation; CpG Islands; DNA Methylation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Oxides; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-kit; RNA, Messenger; Transcriptional Activation; Up-Regulation | 2009 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Cell Division; Cell Survival; DNA Fragmentation; DNA, Neoplasm; Humans; Interphase; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Oxides; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 1998 |